Expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer.

ABSTRACT:

Background

The addition of carbogen and nicotinamide (CON) to radiotherapy (RT) improves overall survival in invasive bladder cancer. We explored whether expression of the hypoxia marker hypoxia-inducible factor-1α (HIF-1α) alone or in combination with other markers predicted benefit from CON.

Methods

A retrospective study was carried out using material from patients with high-grade invasive bladder carcinoma enrolled in the BCON phase III trial of RT alone or with CON (RT+CON). HIF-1α expression was studied in 137 tumours using tissue microarrays and immunohistochemistry. Data were available from other studies for carbonic anhydrase IX and glucose transporter 1 protein and gene expression and tumour necrosis.

Results

Patients with high HIF-1α expression had improved

SUBMITTER: Hunter BA 

PROVIDER: S-EPMC4119984 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature